- Home
- JAGX vs MGTX Comparison
JAGX vs MGTX Comparison
Compare JAGX & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAGX
- MGTX
- Stock Information
- Founded
- JAGX 2013
- MGTX 2015
- Country
- JAGX United States
- MGTX United States
- Employees
- JAGX 49
- MGTX N/A
- Industry
- JAGX Biotechnology: Pharmaceutical Preparations
- MGTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JAGX Health Care
- MGTX Health Care
- Exchange
- JAGX Nasdaq
- MGTX Nasdaq
- Market Cap
- JAGX 3.1M
- MGTX N/A
- IPO Year
- JAGX N/A
- MGTX N/A
- Fundamental
- Price
- JAGX $4.85
- MGTX $6.24
- Analyst Decision
- JAGX
- MGTX Strong Buy
- Analyst Count
- JAGX 0
- MGTX 2
- Target Price
- JAGX N/A
- MGTX $24.50
- AVG Volume (30 Days)
- JAGX 37.8K
- MGTX 799.9K
- Earning Date
- JAGX 03-31-2025
- MGTX 03-13-2025
- Dividend Yield
- JAGX N/A
- MGTX N/A
- EPS Growth
- JAGX N/A
- MGTX N/A
- EPS
- JAGX N/A
- MGTX N/A
- Revenue
- JAGX $11,689,000.00
- MGTX $33,279,000.00
- Revenue This Year
- JAGX $18.18
- MGTX $468.38
- Revenue Next Year
- JAGX $40.06
- MGTX $19.26
- P/E Ratio
- JAGX N/A
- MGTX N/A
- Revenue Growth
- JAGX 19.75
- MGTX 137.42
- 52 Week Low
- JAGX $4.41
- MGTX $3.85
- 52 Week High
- JAGX $540.00
- MGTX $8.75
- Technical
- Relative Strength Index (RSI)
- JAGX 20.48
- MGTX 41.99
- Support Level
- JAGX $4.41
- MGTX $7.13
- Resistance Level
- JAGX $5.45
- MGTX $7.53
- Average True Range (ATR)
- JAGX 0.95
- MGTX 0.51
- MACD
- JAGX 0.00
- MGTX -0.11
- Stochastic Oscillator
- JAGX 3.54
- MGTX 4.74
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.